Gastrointestinal Endoscopy
Volume 70, Issue 5 , Pages 867-873 , November 2009

Screening for Barrett's esophagus in asymptomatic women

  • Lauren B. Gerson, MD, MSc, FASGE

      Affiliations

    • Corresponding Author InformationReprint requests: Lauren B. Gerson, MD, MSc, Division of Gastroenterology, Stanford University School of Medicine, A149, 300 Pasteur Drive, Stanford, CA 94305-5202.
    • ,
  • Subhas Banerjee, MD

Received 29 October 2008 ,Accepted 24 April 2009.

References 

  1. Kim SL, Wo JM, Hunter JG, et al. The prevalence of intestinal metaplasia in patients with and without peptic strictures. Am J Gastroenterol. 1998;93:53–55
  2. Gerson LB, Edson R, Lavori PW, et al. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol. 2001;96:2005–2012
  3. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med. 1998;158:2373–2376
  4. Voutilainen M, Sipponen P, Mecklin JP, et al. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion. 2000;61:6–13
  5. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology. 2002;123:461–467
  6. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677
  7. Lin M, Gerson LB, Lascar R, et al. Features of gastroesophageal reflux disease in women. Am J Gastroenterol. 2004;99:1442–1447
  8. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184–1187
  9. Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003;290:66–72
  10. El-Serag HB, Kvapil P, Hacken-Bitar J, et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol. 2005;100:2151–2156
  11. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130:883–890
  12. Stein DJ, El-Serag HB, Kuczynski J, et al. The association of body mass index with Barrett's oesophagus. Aliment Pharmacol Ther. 2005;22:1005–1010
  13. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–1399
  14. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831
  15. Velanovich V. Comparison of generic (SF-36) vs. disease-specific (GERD-HRQL) quality-of-life scales for gastroesophageal reflux disease. J Gastrointest Surg. 1998;2:141–145
  16. Guillem PG. How to make a Barrett esophagus: pathophysiology of columnar metaplasia of the esophagus. Dig Dis Sci. 2005;50:415–424
  17. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21:953–956
  18. Stoltey J, Reeba H, Ullah N, et al. Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease?. Aliment Pharmacol Ther. 2007;25:83–91
  19. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol. 1997;92:1293–1297
  20. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology. 2007;133:34–41
  21. Gordon C, Kang JY, Neild PJ, et al. The role of the hiatus hernia in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:719–732
  22. Vizcaino AP, Moreno V, Lambert R, et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002;99:860–868
  23. Lofdahl HE, Lu Y, Lagergren J. Sex-specific risk factor profile in oesophageal adenocarcinoma. Br J Cancer. 2008;99:1506–1510
  24. Lagergren J, Jansson C. Sex hormones and oesophageal adenocarcinoma: influence of childbearing?. Br J Cancer. 2005;93:859–861
  25. Lindblad M, Garcia Rodriguez LA, Chandanos E, et al. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer. 2006;94:136–141
  26. Abrams JA, Fields S, Lightdale CJ, et al. Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol. 2008;6:30–34
  27. Benipal P, Garewal HS, Sampliner RE, et al. Short segment Barrett's esophagus: relationship of age with extent of intestinal metaplasia. Am J Gastroenterol. 2001;96:3084–3088
  28. Corley DA, Kubo A, Levin TR, et al. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut. 2009;58:182–188

 DISCLOSURE: The following author disclosed financial relationships relevant to this publication: L. B. Gerson: speaker for AstraZeneca, Takeda Pharmaceuticals, and Santarus. Supported by a grant from the Estelle Buel Simon Fund at Stanford University and an American Gastroenterological Association Research Scholar Award to L. B. Gerson. The other author disclosed no financial relationships relevant to this publication.

PII: S0016-5107(09)01901-4

doi: 10.1016/j.gie.2009.04.053

Gastrointestinal Endoscopy
Volume 70, Issue 5 , Pages 867-873 , November 2009

Article Tools

* Image Usage & Resolution